Emisphere Technologies

Enhancing Oral Formulations of Large and Polar APIs

Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion

Emisphere Technologies has announced that it has reached an agreement with MHR Fund Management to waive certain terms of the company's existing obligations under the loan...

Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion

Emisphere Highlights Eligen Licensee Novo Nordisk's Entry into Phase 3A Development of Oral Semaglutide

Emisphere Technologies has highlighted that Eligen licensee Novo Nordisk will initiate a global phase 3A development programme with oral semaglutide, a once daily oral formulation of...

Emisphere Highlights Eligen Licensee Novo Nordisk's Entry into Phase 3A Development of Oral Semaglutide

Emisphere Signs License Agreement with Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications

Emisphere Technologies has announced it has entered a development and license agreement with Novo Nordisk to develop and commercialise oral formulations of four classes of Novo...

Emisphere Signs License Agreement with Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications

Emisphere Launches Eligen B12, the First Oral Prescription Tablet Proven to Normalize B12 Levels Without an Injection

Emisphere Technologies has announced US commercial availability of Eligen B12, the first and only once-daily oral prescription medical food tablet shown to normalise B12 levels without the need...

Emisphere Launches Eligen B12, the First Oral Prescription Tablet Proven to Normalize B12 Levels Without an Injection

Emisphere Announces Positive Phase II OG217SC Data from Eligen Licensee Novo Nordisk

Emisphere Technologies has announced positive Phase II data from Eligen licensee Novo Nordisk concerning...

Emisphere Announces Positive Phase II OG217SC Data from Eligen Licensee Novo Nordisk